Axsome Therapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $319.9M | $305.1M | $322.9M | $325.3M | $303.0M | $300.9M | $315.4M | $327.3M |
| Accounts Receivable | $277.5M | $251.1M | $224.5M | $196.5M | $198.8M | $161.4M | $142.0M | $124.1M |
| Inventory | $37.9M | $31.5M | $27.9M | $23.8M | $18.4M | $16.3M | $15.7M | $14.3M |
| Total Current Assets | $656.6M | $611.2M | $589.0M | $565.3M | $536.6M | $494.6M | $485.1M | $479.1M |
| Property, Plant & Equipment | $874.0K | $567.0K | $562.0K | $605.0K | $667.0K | $773.0K | $584.0K | $683.0K |
| Goodwill | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M |
| Intangible Assets (Excl. Goodwill) | $37.4M | $38.9M | $40.5M | $42.1M | $43.7M | $45.3M | $46.9M | $48.5M |
| Total Assets | $761.4M | $713.6M | $689.8M | $669.3M | $639.8M | $596.7M | $568.5M | $561.5M |
| Liabilities | ||||||||
| Accounts Payable | $79.0M | $106.7M | $65.5M | $54.2M | $91.6M | $85.7M | $72.0M | $64.3M |
| Total Current Liabilities | $460.4M | $439.2M | $378.8M | $360.3M | $342.1M | $243.9M | $230.1M | $196.2M |
| Long-Term Debt | $118.0M | $117.9M | $117.7M | $117.6M | $117.5M | $181.4M | $180.7M | $180.0M |
| Total Liabilities | $678.1M | $659.0M | $601.5M | $595.5M | $566.7M | $543.5M | $511.5M | $468.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.42B | $-1.37B | $-1.31B | $-1.28B | $-1.23B | $-1.18B | $-1.12B | $-1.05B |
| Total Stockholders' Equity | $83.3M | $54.6M | $88.3M | $73.7M | $73.1M | $53.2M | $57.0M | $92.9M |